Compositions and their uses

Abstract

Provided is a composition in which a cosmetic active ingredient is supported on platinum particles, and the composition improves the delivery efficiency of the platinum particles on the skin surface. 【Solution means】The composition contains a carrier, and the carrier includes liposomes and platinum supported within the liposomes. A cosmetic active ingredient is supported on the surface of the platinum. The weight ratio of the liposomes to the platinum is 100 to 500:1. The cosmetic active ingredient is madecassoside or palmitoyl tripeptide-5. The weight ratio of the platinum to the cosmetic active ingredient is 1:0.1 to 20. The particle diameter of the platinum is 3 to 200 nm. The platinum connects the cosmetic active ingredient by physical action or chemical bonding. The composition is characterized by the above.

Description

Technical Field

[0001] The present invention belongs to the technical field of new cosmetic materials, and specifically relates to a composition and its use.

Background Art

[0002] Noble metal nanoparticles refer to particles formed by stacking a certain number of atoms of noble metals such as Au, Ag, and Pt. The shapes of the particles include various types such as spherical, rod-shaped, flower-shaped, and cubic. The most commonly used ones are spherical. Similarly, by controlling the number of stacked atoms, particles of various sizes can be obtained.

[0003] Noble metal particles themselves can be used as a carrier matrix, and can be combined with biomolecules (such as nucleic acids, antibodies, polypeptides, proteins), drug molecules, fluorescent substances, polymers, etc. to form microparticles with integrated properties, and are widely used in the field of biomedicine. However, this technology has hardly been applied in the cosmetic field.

[0004] The applicant submitted a patent application CN106963658A disclosing a cosmetic composition containing nano-platinum. This composition contains nano-platinum, and through experiments, it has been proven that nano-platinum has the effect of removing all reactive oxygen species in the body and can continue to function in the body. In addition, since nano-platinum is colorless, odorless, safe and harmless, it can also be used as an active ingredient in cosmetics.

[0005] Furthermore, the applicant first proposed platinum-modified liposomes, its manufacturing method and its use in CN107550865A, and demonstrated that liposomes added with platinum have excellent stability and can be stored for a long time while maintaining a small particle size. In addition, in CN107095799A, composite liposomes, its manufacturing method and its use were proposed, and it was demonstrated that platinum was added to liposomes containing grabricine to obtain composite liposomes with synergistic whitening ability and high stability.

[0006] Upon further detailed research on platinum, the applicant discovered other amazing phenomena.

[0007] Furthermore, regarding the application of platinum in cosmetics, reference can also be made to CN106420445B, which discloses a skin care matrix with moisturizing and antioxidant effects, a method for manufacturing the same, and its use. Platinum particles of 2 nm are blended with various active ingredients to form a composition.

[0008] Further research on nano-platinum has shown that the use of this material in cosmetics can be expected.

Summary of the Invention

Problems to be Solved by the Invention

[0009] In view of the drawbacks of the prior art, the first object of the present invention is to provide a composition in which cosmetic active ingredients are carried on platinum particles and platinum particles are carried on liposomes, which improves the dispersion stability of platinum particles by liposomes and also improves the delivery efficiency of platinum particles on the skin surface. Through the stable and efficient delivery of cosmetic active ingredients by platinum particles and the activation of cosmetic active ingredients, high performance can be achieved even when a small amount of cosmetic active ingredients are used. Also, through various experiments on the loading of cosmetic active ingredients, it has been confirmed that the composition has good effects on the delivery and activation of most cosmetic active ingredients.

[0010] The second object of the present invention is to provide the use of the above composition.

Means for Solving the Problems

[0011] To achieve the first object of the invention, the present invention adopts the following technical solutions. A composition comprising a carrier, wherein the carrier comprises liposomes and platinum carried within the liposomes, and a cosmetic active ingredient is carried on the surface of the platinum.

[0012] Liposomes are small, sealed vesicles with a bilayer structure formed by the dispersion of lipidoids such as phospholipids in water. Since their structure resembles that of biological membranes, they are also called artificial biological membranes.

[0013] The composition of liposomes consists of lipidoids (phospholipids) and additives. The phospholipid substances include natural phospholipids and synthetic phospholipids. The structural characteristics of phospholipids are a hydrophilic group composed of one phosphate group and one quaternary ammonium base, and a lipophilic group composed of two longer hydrocarbon groups.

[0014] In the above composition, the particle size of the platinum is 3 to 200 nm.

[0015] In some embodiments of the present invention, the particle size of the platinum is 3 nm, 5 nm, 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 100 nm, 120 nm, 150 nm, 180 nm, or 200 nm, In the above composition, the weight ratio of the liposomes to the platinum is 100 to 500:1.

[0016] In some embodiments of the present invention, the weight ratio of the liposomes to the platinum is 100:1, 200:1, 300:1, 400:1, or 500:1.

[0017] In the above composition, the platinum links the cosmetic active ingredient by physical action or chemical bonding.

[0018] In the above composition, the physical actions are electrostatic interaction, van der Waals force, hydrogen bonding, and hydrophobic interaction, and the chemical bonds are covalent bond, coordination bond, or dangling bond.

[0019] Preferably, the cosmetic active ingredient includes one or more of a fat-soluble active ingredient, a water-soluble active ingredient, an active ingredient with a molecular weight greater than 5000, and a polypeptide.

[0020] In the above composition, the fat-soluble active ingredient is one or more of grabrutin, ceramide, resveratrol, and salicylic acid, the water-soluble active ingredient is one or more of madecassoside, tetrahydromethylpyrimidine carboxylic acid, dipotassium grabrutinate, nicotinamide, and ascorbic acid, the active ingredient with a molecular weight greater than 5000 is one or more of sodium oligo hyaluronate (molecular weight 5 - 10 kDa), medium molecular weight sodium hyaluronate (molecular weight 80 - 1.5 million Da), high molecular weight sodium hyaluronate (> 1.8 million Da), β-glucan, sodium acetyl hyaluronate, and sodium heparin, the polypeptide is one or more of palmitoyl tripeptide - 5, hexapeptide - 11, hexapeptide - 9, L - carnosine, acetyl dipeptide - 1 cetyl ester, palmitoyl tripeptide - 1, palmitoyl tetrapeptide - 7, palmitoyl pentapeptide - 4, nonapeptide - 1, acetyl tetrapeptide - 2, and tetrapeptide - 1.

[0021] In the above composition, the weight ratio of the platinum to the cosmetic active ingredient is 1:0.1 - 20.

[0022] Preferably, the weight ratio of the platinum to the cosmetic active ingredient is 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:10, 1:15, 1:20.

[0023] Finally, the present invention also provides the use of any of the above compositions in the manufacture of cosmetics.

Advantages of the Invention

[0024] Compared with the prior art, the present invention has the following beneficial effects. 1. The composition of the present invention has a cosmetic active ingredient supported on platinum particles, and also has platinum particles supported on liposomes. The liposomes increase the dispersion stability of the platinum particles and improve the delivery efficiency of the platinum particles on the skin surface. By the stable and efficient delivery of the cosmetic active ingredient by the platinum particles and the activation of the cosmetic active ingredient, high performance can be achieved even when a small amount of the cosmetic active ingredient is used. Also, through the loading experiments of various cosmetic active ingredients, it was confirmed that the composition has good effects of delivery and activation on most cosmetic active ingredients. 2. Platinum particles themselves have excellent catalytic action, can reduce the level of reactive oxygen species in the body, and can achieve the protective effect on cells and tissues. By modifying the cosmetic active ingredient on the surface of the platinum particles, the biorecognition and absorption efficiency of the cells for the platinum particles are improved, and the beneficial effects of the platinum particles on the skin are further enhanced.

Brief Description of the Drawings

[0025]

Figure 1A

Figure 1B

Figure 1C

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7A

Figure 7B

Figure 7C

Embodiments for Carrying Out the Invention

[0026] The technical solution of the present invention will be further described below through embodiments for carrying out the invention. Those skilled in the art should understand that these embodiments are only for helping to understand the present invention and should not be regarded as particularly limiting the present invention.

[0027] When specific experimental steps or conditions are not specified in the examples, they can be carried out according to the operations or conditions of the conventional experimental steps described in the literature of the relevant field. When the manufacturers of the reagents and equipment used are not indicated, they are all commercially available conventional reagent products.

[0028] Part 1: Production of Platinum Particles Example 1 Step 1: Production of 20 nm platinum particles Aqueous solutions of ascorbic acid, potassium tetrachloroplatinate, and PVP were prepared in the respective prescribed amounts.

[0029] Ascorbic acid and the PVP aqueous solution were placed in a three-necked flask equipped with a reflux tube and heated until the solution boiled. Then, the potassium tetrachloroplatinate solution was quickly injected into the reaction system, and the reaction was continued for 1 hour. Refer to Table 1 for the specific mixing ratios. Step 2: Purification of platinum particles Using acetone as a precipitant, it was mixed with the platinum particle aqueous dispersion of Step 1 and centrifuged at 6000 rpm for 5 minutes. The weight ratio of acetone to platinum particles was 3000:1. Since platinum particles are insoluble in acetone, they form a precipitate. The supernatant was removed, and the precipitate was retained. An appropriate amount of PVP aqueous solution was added to the obtained precipitate and uniformly dispersed to obtain a platinum particle aqueous dispersion. This process was repeated 3 times. Finally, it was diluted with pure water until the platinum content became a solution of 1000 ppm, and a 20 nm platinum particle solution was obtained.

[0030] Example 2 Step 1: Production of 100 nm platinum particles Aqueous solutions of ascorbic acid, potassium tetrachloroplatinate, potassium iodide, and PVP were prepared in the respective prescribed amounts. Ascorbic acid, potassium iodide, the PVP aqueous solution, and 20 μL of the platinum particle solution of Example 1 were placed in a three-necked flask equipped with a reflux tube and heated to 90°C. Then, the potassium tetrachloroplatinate solution was slowly dropped into the reaction system, and the reaction was continued for 1 hour.

[0031] Refer to Table 1 for the specific mixing ratios. Step 2: Purification of platinum particles Using acetone as a precipitant, it was mixed with the platinum particle aqueous dispersion of Step 1 and centrifuged at 6000 rpm for 5 minutes. The weight ratio of acetone to platinum particles is 3000:1. Since the platinum particles are insoluble in acetone, they precipitate. The supernatant was removed and the precipitate was retained. An appropriate amount of PVP aqueous solution was added to the obtained precipitate and dispersed uniformly to obtain a platinum particle aqueous dispersion. This process was repeated three times. Finally, it was diluted with pure water until a solution with a platinum content of 1000 ppm was obtained to obtain a 100 nm platinum particle solution.

[0032] Example 3 Step 1: Production of 200 nm platinum particles Prescription amounts of ascorbic acid aqueous solution, potassium tetrachloroplatinate aqueous solution, potassium iodide aqueous solution, and PVP aqueous solution were prepared respectively. Ascorbic acid, potassium iodide, PVP aqueous solution and 10 μL of the platinum particle solution of Example 1 were put into a three-necked flask with a reflux tube, and when the solution was heated to 80 °C, the potassium tetrachloroplatinate solution was slowly dropped into the reaction system, and the reaction was continued for 2 hours.

[0033] Refer to Table 1 for the specific mixing ratio. Step 2: Purification of platinum particles Using acetone as a precipitant, it was mixed with the platinum particle aqueous dispersion in Step 1 and centrifuged at 6000 rpm for 5 minutes. The weight ratio of acetone to platinum particles is 3000:1. Since the platinum particles are insoluble in acetone, they precipitate. The supernatant was removed and the precipitate was retained. An appropriate amount of PVP aqueous solution was added to the obtained precipitate and dispersed uniformly to obtain a platinum particle aqueous dispersion. This process was repeated three times. Finally, it was diluted with pure water until a solution with a platinum content of 1000 ppm was obtained to obtain a 200 nm platinum particle solution.

[0034] Synthesis prescription table of platinum particles JPEG0007712457000002.jpg47170

[0035] Part 2: Loading of active ingredient Example 4 Glabridin was loaded onto the product of Example 1, and semi-finished product 1, semi-finished product 2, and semi-finished product 3 were produced according to the loading amount. Step 1: To 1 ml of the platinum particle solution of Example 1 (platinum particle concentration: 1000 ppm), 1 / 10 of the volume of diethylamine was added, and the mixture was slowly stirred at room temperature for 24 hours. An appropriate amount of the mixed solution was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles is 3000:1. The function of diethylamine is to separate platinum particles and PVP by competitive binding and connect diethylamine to the surface of platinum particles. Step 2: After centrifugation, the supernatant was removed and the precipitate was retained. 2 ml of 20% aqueous acetic acid solution was added to the obtained precipitate and dispersed uniformly to obtain a platinum particle dispersion. The function of acetic acid is to weaken the binding force between diethylamine and platinum particles by neutralizing diethylamine so that the platinum particles obtained in Step 3 become platinum particles without a carrier. Step 3: An appropriate amount of the platinum particle dispersion of Step 2 was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles is 3000:1. Step 4: After centrifugation, the supernatant was removed and the precipitate was retained. 1 ml of 1000 / 2500 / 5000 ppm of grabrizine ethanol solution (100% ethanol solution) was added to the obtained precipitate respectively and dispersed uniformly to obtain ethanol solutions of platinum particles supported with different contents of grabrizine, which were designated as semi-finished product 1, semi-finished product 2, and semi-finished product 3 respectively.

[0036] Example 5 Madecassoside was supported on the product of Example 2, and semi-finished product 4, semi-finished product 5, and semi-finished product 6 were manufactured according to the loading amount. Step 1: To 1 ml of the platinum particle solution of Example 2 (platinum particle concentration: 1000 ppm), 1 / 10 of the volume of diethylamine was added, and the mixture was slowly stirred at room temperature for 24 hours. An appropriate amount of the mixed solution was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles is 3000:1. Step 2: After centrifugation, the supernatant was removed and the precipitate was retained. 2 ml of 20% aqueous acetic acid solution was added to the obtained precipitate and dispersed uniformly to obtain a platinum particle dispersion. Step 3: An appropriate amount of the platinum particle dispersion of Step 2 was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles was 3000:1. Step 4: After centrifugation, the supernatant was removed and the precipitate was retained. 1 ml of 1000 / 2500 / 5000 ppm madekassoside aqueous solution was added to the obtained precipitate respectively and uniformly dispersed to obtain aqueous solutions of platinum particles supporting madekassoside with various contents, which were designated as semi-finished product 4, semi-finished product 5, and semi-finished product 6 respectively.

[0037] Example 6 Hyaluronic acid was supported on the product of Example 3, and semi-finished product 7, semi-finished product 8, and semi-finished product 9 were produced according to the loading amount. Step 1: 1 / 10 of the volume of diethylamine was added to 1 ml of the platinum particle solution of Example 3 (platinum particle concentration: 1000 ppm), and the mixture was slowly stirred at room temperature for 24 hours. An appropriate amount of the mixture was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles is 3000:1. Step 2: After centrifugation, the supernatant was removed and the precipitate was retained. 2 ml of 20% acetic acid aqueous solution was added to the obtained precipitate and uniformly dispersed to obtain a platinum particle dispersion. Step 3: An appropriate amount of the platinum particle dispersion of Step 2 was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles was 3000:1. Step 4: After centrifugation, the supernatant was removed and the precipitate was retained. 1 ml of 1000 / 2500 / 5000 ppm sodium oligo-hyaluronate (molecular weight 5 - 8 kDa) aqueous solution was added to the obtained precipitate respectively and uniformly dispersed to obtain aqueous solutions of platinum particles supporting hyaluronic acid with various contents, which were designated as semi-finished product 7, semi-finished product 8, and semi-finished product 9 respectively.

[0038] Example 7 Palmitoyl tripeptide-5 was supported on the product of Example 1, and semi-finished product 10, semi-finished product 11, and semi-finished product 12 were produced according to the loading amount. Step 1: 1 ml of the platinum particle solution of Example 1 (platinum particle concentration: 1000 ppm) was added with diethylamine at 1 / 10 of its volume and slowly stirred at room temperature for 24 hours. An appropriate amount of the mixed solution was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles was 3000:1. Step 2: After centrifugation, the supernatant was removed and the precipitate was retained. 2 ml of 20% aqueous acetic acid solution was added to the obtained precipitate and uniformly dispersed to obtain a platinum particle dispersion. Step 3: An appropriate amount of the platinum particle dispersion of Step 2 was mixed with acetone and centrifuged at 8000 rpm for 3 minutes. The weight ratio of acetone to platinum particles was 3000:1. Step 4: After centrifugation, the supernatant was removed and the precipitate was retained. 1 ml of palmitoyl tripeptide-5 ethanol solution (100% ethanol solution) at 1000 / 2500 / 5000 ppm was added to the obtained precipitate respectively and uniformly dispersed to obtain ethanol solutions of platinum particles carrying palmitoyl tripeptide-5 at various contents, which were respectively designated as semi-finished product 10, semi-finished product 11, and semi-finished product 12.

[0039] Part 3: Production of Liposomes Example 8 (1) Weighed 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, 0.15 g of meadowfoam oil, and 16 g of the ethanol solution of platinum particles carrying grabrizine (semi-finished products 1 to 3), added them to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2), and completely dissolved them. (2) The above organic solvent mixture was put into a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to 50 mbar finally; temperature: 65 °C) to form a dry film. A mixed solution of 30% by mass of butanediol and water was weighed into the rotary evaporation flask and hydrated until the film eluted to obtain a liposome suspension. (3) The above liposome suspension was homogenized with a high-pressure homogenizer at a pressure of 800 bar to obtain a platinum particle composition liposome. The final liposome had a platinum content of 160 ppm and was designated as Sample 1-3.

[0040] Example 9 Production of Samples 4-6 Using Semi-finished Products 4-6 (1) 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, and 0.15 g of meadowfoam oil were weighed and added to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2) and completely dissolved. (2) The above organic solvent mixture was placed in a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to a final pressure of 50 mbar; temperature: 65 °C) to form a dry film. 16 g of a mixed solution of 30% by mass of butanediol and water and an aqueous solution of platinum particles supported on m-decaside (semi-finished products 4 to 6) were weighed into a rotary evaporation flask and hydrated until the film eluted to obtain a liposome suspension. (3) The above liposome suspension was homogenized with a high-pressure homogenizer at a pressure of 800 bar to obtain a platinum particle composition liposome. The final liposome had a platinum content of 160 ppm and was designated as Sample 4-6.

[0041] Example 10 Production of Samples 7-9 Using Semi-finished Products 7-8 (1) 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, and 0.15 g of meadowfoam oil were weighed and added to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2) and completely dissolved. (2) The above organic solvent mixture was placed in a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to finally 50 mbar; temperature: 65 °C) to form a dry film. A mixed solution of 30% by mass of butanediol and water, and 16 g of an aqueous solution of platinum particles supporting hyaluronic acid (semi-finished products 7 to 9) were weighed into a rotary evaporation flask, hydrated until the film eluted, and a liposome suspension was obtained. (3) The above liposome suspension was homogenized at a pressure of 800 bar using a high-pressure homogenizer to obtain a platinum particle composition liposome. The final liposome had a platinum content of 160 ppm and was designated as samples 7 - 9.

[0042] Example 11 Production of Samples 10 - 12 Using Semi-finished Products 10 - 12 (1) 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, 0.15 g of meadowfoam oil, and 16 g of an ethanol solution of platinum particles supporting palmitoyl tripeptide - 5 (semi-finished products 10 to 12) were weighed and added to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2) and completely dissolved. (2) The above organic solvent mixture was placed in a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to finally 50 mbar; temperature: 65 °C) to form a dry film. A mixed solution of 30% by mass of butanediol and water was weighed into a rotary evaporation flask, hydrated until the film eluted, and a liposome suspension was obtained. (3) The above liposome suspension was homogenized at a pressure of 800 bar using a high-pressure homogenizer to obtain a platinum particle composition liposome. The final liposome had a platinum content of 160 ppm and was designated as samples 10 - 12.

[0043] Part 4 Production of Comparative Samples Comparative Example 1 (1) Weighed 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, 0.15 g of meadow foam oil, and 0.016 g of grabiline, added 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2), and dissolved completely. (2) Put the above organic solvent mixture into a rotary evaporator, and under reduced pressure conditions (pressure: gradually reduced from normal pressure to finally 50 mbar. Temperature: 65 °C), the organic solvent was rotary evaporated to form a dry film. A mixed solution of 30% by mass of butanediol and water was weighed into the rotary evaporation flask, and hydrated until the film eluted to obtain a liposome suspension. (3) The above liposome suspension was homogenized at a pressure of 800 bar by a high-pressure homogenizer to obtain a liposome solution of grabiline alone. The grabiline in the grabiline liposome solution had a concentration of 160 ppm and was used as Comparative Sample 1.

[0044] Comparative Example 2 (1) Weighed 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, 0.15 g of meadow foam oil, and 0.016 g of grabiline, added it to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2), and dissolved completely. (2) Put the above organic solvent mixture into a rotary evaporator, and under reduced pressure conditions (pressure: gradually reduced from normal pressure to finally 50 mbar. Temperature: 65 °C), the organic solvent was rotary evaporated to form a dry film. A mixed solution of 30% by mass of butanediol and water, and 16 g of the platinum particle solution of Example 1 were weighed into the rotary evaporation flask, and hydrated until the film eluted to obtain a liposome suspension. (3) The above liposome suspension was homogenized at a pressure of 800 bar by a high-pressure homogenizer to obtain a liposome solution in which both grabiline and platinum particles were encapsulated, and it was used as Comparative Sample 2. The concentration of both grabiline and platinum particles in the liposome solution was 160 ppm, and it was used as Comparative Sample 2.

[0045] Comparative Example 3 The platinum particle dispersion of Example 1 and grabiline powder were added to a mixed solvent of 30% by mass of butanediol and water so that the concentrations of both platinum particles and grabiline were 100 ppm, to obtain Comparative Sample 3. Blank Sample 1 Grabiline powder was dissolved in a mixed solvent of 30% by mass of butanediol and water so that the concentration of grabiline was 100 ppm, to obtain Comparative Sample 4.

[0046] Comparative Example 4 (1) 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, and 0.15 g of meadowfoam oil were weighed and added to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2), and completely dissolved. (2) The above organic solvent mixture was placed in a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to 50 mbar finally; temperature: 65 °C) to form a dry film. A mixed solution of 30% by mass of butanediol and water, and 0.04 g of mdecasoside were weighed into the rotary evaporation flask, and hydrated until the film eluted to obtain a liposome suspension. (3) The above liposome suspension was homogenized by a high-pressure homogenizer at a pressure of 800 bar to obtain a liposome solution of mdecasoside alone. The mdecasoside liposome solution had a concentration of mdecasoside of 400 ppm and was used as Comparative Sample 5.

[0047] Comparative Example 5 (1) 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, and 0.15 g of meadowfoam oil were weighed and added to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2), and completely dissolved. (2) The above organic solvent mixture was placed in a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to a final pressure of 50 mbar; temperature: 65 °C) to form a dry film. A mixed solution of 30% by mass of butanediol and water, 0.04 g of madeksoside, and 16 g of the platinum particle solution of Example 2 were weighed into a rotary evaporation flask, hydrated until the film eluted, and a liposome suspension was obtained. (3) The above liposome suspension was homogenized by a high-pressure homogenizer at a pressure of 800 bar to obtain a liposome solution in which madeksoside and platinum particles were encapsulated. The liposome solution had a madeksoside concentration of 400 ppm and a platinum particle concentration of 160 ppm, and was used as Comparative Sample 6.

[0048] Comparative Example 6 The platinum particle dispersion of Example 2 and madeksoside powder were added to a mixed solvent of 30% by mass of butanediol and water so that the platinum particle concentration was 100 ppm and the madeksoside concentration was 250 ppm, and it was used as Comparative Sample 7. Blank Sample 2 Madeksoside powder was dissolved in a mixed solvent of 30% by mass of butanediol and water so that the madeksoside concentration was 250 ppm, and it was used as Comparative Sample 8.

[0049] Comparative Example 7 (1) 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, and 0.15 g of meadowfoam oil were weighed and added to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2) and completely dissolved. (2) The above organic solvent mixture was placed in a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to a final pressure of 50 mbar; temperature: 65 °C) to form a dry film. A mixed solution of 30% by mass of butanediol and water and 0.08 g of sodium oligo-hyaluronate were weighed into a rotary evaporation flask, hydrated until the film eluted, and a liposome suspension was obtained. (3) The above liposome suspension was homogenized with a high-pressure homogenizer at a pressure of 800 bar to obtain a liposome solution of sodium oligo hyaluronate alone. The sodium oligo hyaluronate liposome solution had a concentration of sodium oligo hyaluronate of 800 ppm and was used as Comparative Sample 9.

[0050] Comparative Example 8 (1) 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, and 0.15 g of meadowfoam oil were weighed and added to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2) and completely dissolved. (2) The above organic solvent mixture was placed in a rotary evaporator, and the organic solvent was rotary evaporated under reduced pressure conditions (pressure: gradually reduced from normal pressure to a final pressure of 50 mbar; temperature: 65 °C) to form a dry film. A mixed solution of 30% by mass of butanediol and water, 0.08 g of sodium oligo hyaluronate, and 16 g of the platinum particle solution of Example 3 were weighed into a rotary evaporation flask and hydrated until the film eluted to obtain a liposome suspension. (3) The above liposome suspension was homogenized with a high-pressure homogenizer at a pressure of 800 bar to obtain a liposome solution encapsulating sodium oligo hyaluronate and platinum particles. The liposome solution had a concentration of sodium oligo hyaluronate of 800 ppm and a concentration of platinum particles of 160 ppm and was used as Comparative Sample 10.

[0051] Comparative Example 9 The platinum particle dispersion of Example 3 and sodium oligo hyaluronate powder were added to a mixed solvent of 30% by mass of butanediol and water so that the concentration of platinum particles was 100 ppm and the concentration of sodium oligo hyaluronate was 500 ppm, and it was used as Comparative Sample 11. Blank Sample 3 Sodium oligo hyaluronate powder was dissolved in a mixed solvent of 30% by mass of butanediol and water so that the concentration of sodium oligo hyaluronate was 500 ppm, and it was used as Comparative Sample 12.

[0052] Comparative Example 10 (1) Weighed 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, 0.15 g of meadowfoam oil, and 0.016 g of palmitoyl tripeptide-5, added them to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2), and dissolved them completely. (2) Put the above organic solvent mixture into a rotary evaporator, and rotate-evaporate the organic solvent under reduced pressure conditions (pressure: gradually reduced from normal pressure to finally 50 mbar; temperature: 65 °C) to form a dry film. Weighed a mixed solution of 30% by mass of butanediol and water into the rotary evaporation flask, hydrated until the film eluted, and obtained a liposome suspension. (3) Homogenized the above liposome suspension with a high-pressure homogenizer at a pressure of 800 bar to obtain a liposome solution of palmitoyl tripeptide-5 alone. The concentration of palmitoyl tripeptide-5 in the liposome solution was 160 ppm, which was used as Comparative Sample 13.

[0053] Comparative Example 11 (1) Weighed 2.5 g of hydrogenated lecithin, 0.5 g of ceramide NP, 0.25 g of cholesterol, 0.15 g of meadowfoam oil, and 0.016 g of palmitoyl tripeptide-5, added them to 140 ml of an organic solvent (a mixed solution of methanol and dichloromethane with a volume ratio of 5:2), and dissolved them completely. (2) Put the above organic solvent mixture into a rotary evaporator, and rotate-evaporate the organic solvent under reduced pressure conditions (pressure: gradually reduced from normal pressure to finally 50 mbar; temperature: 65 °C) to form a dry film. Weighed a mixed solution of 30% by mass of butanediol and water, and 16 g of the platinum particle aqueous solution of Example 1 into the rotary evaporation flask, hydrated until the film eluted, and obtained a liposome suspension. (3) Homogenized the above liposome suspension with a high-pressure homogenizer at a pressure of 800 bar to obtain a liposome solution in which both palmitoyl tripeptide-5 and platinum particles were encapsulated. The concentration of both palmitoyl tripeptide-5 and platinum particles in the liposome solution was 160 ppm, which was used as Comparative Sample 14.

[0054] Comparative Example 12 The platinum particle dispersion of Example 1 and palmitoyl tripeptide-5 powder were added to ethanol so that the concentrations of both platinum particles and palmitoyl tripeptide-5 became 100 ppm, and Comparative Sample 15 was obtained. Blank Sample 4 Palmitoyl tripeptide-5 powder was dissolved in ethanol so that the concentration of palmitoyl tripeptide-5 became 100 ppm, and Comparative Sample 16 was obtained.

[0055] Part 5: Tests on Physical and Chemical Properties 1. Test on Particle Size after Encapsulation with Platinum Particles and Liposomes of Various Sizes Dynamic Light Scattering (DLS): Before the test, first, the sample was diluted to 1% with pure water and sonicated for 2 minutes. Then, the diluted solution was put into a sample cell, and the average particle size (unit: nanometer), polydispersity index (PDI), and Zeta potential (unit: mV) of the sample were measured using a Malvern Zetasizer Advance device.

[0056] The particle size distributions of Examples 1 to 3 can be referred to in FIGS. 1A to 1C. The statistical results of the particle size and the results of the polydispersity index are shown in Table 2.

[0057] Statistical Results of Particle Size, Polydispersity Index, and Zeta Potential of Platinum Particles of Various Sizes JPEG0007712457000003.jpg42170

[0058] It was found from Table 2 that Examples 1 to 3 of the present invention all produced platinum particles having a desired particle size.

[0059] Statistical Results of Particle Size, Polydispersity Index, and Zeta Potential of Platinum Particles of Various Sizes Supporting Active Substances JPEG0007712457000004.jpg54170

[0060] From Table 3, in Samples 1 to 12, although the particle size of the particles carrying the active ingredient did not change significantly, the Zeta potential changed significantly. From the perspective of the Zeta potential, it was found that the platinum particles of the present invention carried the active ingredient well.

[0061] Statistical results of the particle size of various platinum particle liposomes and results of the polydispersity coefficient JPEG0007712457000005.jpg49170

[0062] 2. Infrared spectra before and after loading the active substance Pretreatment of the sample: A poor solvent (that is, a solvent in which the corresponding active substance is insoluble, for example, water in the case of glabridin, tetrahydrofuran in the case of madekassoside, acetone in the case of sodium hyaluronate, and water in the case of palmitoyl tripeptide-5) was used for the samples of the examples, and centrifuged at 8000 rpm for 10 minutes. The supernatant was discarded and the precipitate was retained. It was redispersed using a solvent in which the active substance was soluble, the poor solvent was repeatedly added, centrifuged, and precipitated. This was repeated twice, and the precipitate was collected. The purpose of multiple washings is to remove the active substance not carried on the platinum particles.

[0063] Test of infrared spectrum: An appropriate amount of sample powder and potassium bromide were mixed and ground to form a fine powder. The ground powder was put into a hydraulic press and pressed into a thin flake, and tested in transmission mode using a Thermo Scientific Nicolte iS50 Fourier transform infrared spectrometer to measure the infrared spectrum of the sample.

[0064] Refer to Figures 2 to 6 for the test results. In Figure 2, in the range of 500 cm -1 ~1500 cm -1 2900 cm -1 3300 cm -1 and 3500 cm -1It was found from the spectrum that there is an infrared absorption characteristic peak of the grabridin molecular group near . Platinum particles themselves do not have a characteristic peak in the above range, but when grabridin is supported by surface modification, a characteristic peak in the above range appears, indicating that the platinum particles have successfully supported the grabridin molecules.

[0065] In FIGS. 3 and 4, it was found from the spectrum that the group of the madekasoside molecule has significant infrared absorption near 1000 cm -1 The platinum particles supporting madekasoside show absorption near 1000 cm -1 compared with before loading, indicating that they are well combined with the madekasoside molecules.

[0066] In FIG. 5, it was found from the spectrum that the range of 1000 cm -1 to 1700 cm -1 is the infrared absorption characteristic peak of the sodium hyaluronate molecular group. The characteristic peak in the above range of the platinum particles after loading coincides with the characteristic peak of sodium hyaluronate, indicating that the platinum particles can successfully support sodium hyaluronate molecules with various molecular weights.

[0067] In FIG. 6, it was found from the spectrum that the ranges of 600 cm -1 to 1700 cm -1 and 2750 cm -1 to 3300 cm -1 are the infrared absorption characteristic peaks of the palmitoyl tripeptide-5 molecular group. Platinum particles themselves do not have a characteristic peak in the above range, but when palmitoyl tripeptide-5 is supported by surface modification, a characteristic peak in the above range appears, indicating that the platinum particles have successfully supported the palmitoyl tripeptide-5 molecules.

[0068] From FIGS. 2 to 6, it can be proved that the platinum particles of the present invention have successfully supported the active ingredient.

[0069] 3. Changes in solubility before and after loading the active substance Change in solubility of the sample carrying grabrigin: 2:5 0.5 g of an ethanol solution of platinum particles carrying 2500 ppm of grabrigin (semi-finished product 2 of Example 4 (platinum concentration 1000 ppm, grabrigin concentration 2500 ppm)) was added with 5 g of pure water, placed in a centrifuge, and centrifuged at 3000 rpm for 3 minutes. Also, 0.5 g of platinum particles not carrying grabrigin (Example 1, platinum concentration 1000 ppm) was added with 0.5 g of an ethanol solution containing 0.25% grabrigin, further added with 4.5 g of pure water, uniformly mixed, placed in a centrifuge, and centrifuged at 3000 rpm for 3 minutes. The observed phenomena were compared.

[0070] Change in solubility of the sample carrying palmitoyl tripeptide-5: 1:5 0.5 g of an ethanol solution of platinum particles carrying 5000 ppm of palmitoyl tripeptide-5 (semi-finished product 12 of Example 7 (platinum concentration 1000 ppm, palmitoyl tripeptide-5 concentration 5000 ppm)) was added with 5 g of pure water, placed in a centrifuge, and centrifuged at 3000 rpm for 3 minutes. Also, 0.5 g of platinum particles not carrying palmitoyl tripeptide-5 (Example 1, platinum concentration 1000 ppm) was added with 0.5 g of an ethanol solution containing 0.5% palmitoyl tripeptide-5, further added with 4.5 g of pure water, uniformly mixed, placed in a centrifuge, and centrifuged at 3000 rpm for 3 minutes. The observed phenomena were compared.

[0071] Change in solubility of the sample carrying ceramide: 1 ml of an ethanol solution of platinum particles carrying ceramide, 1 ml of pure water, and 1 ml of squalane were mixed, heated and stirred at 70 °C, and then left standing. As a control, 1 ml of an aqueous solution of platinum particles of Example 1, 1 ml of an ethanol solution dissolving an equal mass of ceramide, and 1 ml of squalane were mixed, heated and stirred at 70 °C, and then left standing. The phenomena of the two groups were observed.

[0072] The results of the test are shown in FIGS. 7A to 7C. Figure 7A shows the group carrying glabridin. The sample on the left (Pt-glab) represents platinum particles carrying glabridin manufactured according to the method of the present invention, and the sample on the right (Pt-PVP, glab) represents a sample obtained by simply mixing the platinum particles of Example 1 and glabridin only. Since PVP is easily soluble in water and glabridin is insoluble in water, the platinum particles carrying glabridin can be centrifuged with water to form a black precipitate, while the simply mixed sample cannot be centrifuged to form a precipitate. This indicates that the present invention can successfully carry the active substance, thereby changing the dissolution characteristics of the surface of the platinum particles, while the simple mixing method cannot successfully carry the active substance. Figure 7B shows the group carrying palmitoyl tripeptide-5. The sample on the left (Pt-ptp5) represents platinum particles carrying palmitoyl tripeptide-5 manufactured according to the method of the present invention, and the sample on the right (Pt-PVP, ptp5) represents a sample obtained by simply mixing the platinum particles of Example 1 and palmitoyl tripeptide-5 only. Since PVP is easily soluble in water and palmitoyl tripeptide-5 is insoluble in water, the platinum particles carrying palmitoyl tripeptide-5 can be centrifuged with water to form a black precipitate, while the simply mixed sample cannot be centrifuged to form a precipitate. This indicates that the present invention can successfully carry the active substance, thereby changing the dissolution characteristics of the surface of the platinum particles, while the simple mixing method cannot successfully carry the active substance. Figure 7C shows the group carrying ceramide. The sample on the right (Pt-ceramide) represents platinum particles carrying ceramide manufactured according to the method of the present invention, and the sample on the left (Pt-PVP, ceramide) represents a sample obtained by simply mixing the platinum particles of Example 1 and ceramide only. Since ceramide is insoluble in water and soluble in oils and fats, the platinum particles carrying ceramide have high lipophilicity, so the oil layer turns black, while the platinum particles that do not carry ceramide well are hydrophilic, so the water layer does not turn black. This indicates that the present invention can successfully carry the active substance, thereby changing the dissolution characteristics of the surface of the platinum particles, and also shows its versatility.

[0073] Part 6: Test of Applicable Performance 1. Test of Melanin Content in B16 Cells Well-grown B16 cells in the logarithmic growth phase were counted, inoculated into 6-well plates, placed in an incubator at 37°C and 5% CO2 for overnight culture, cultured in a CO2 incubator for 16 h, and then changed to 1% FBS-DMEM and incubated for 6 h.

[0074] 10% FBS-DMEM medium containing the sample was prepared and added to the 6-well plates at 2 ml / well. Solvent control wells, model wells, and experimental wells were set up. Among these, the sample solvent was added to the solvent control wells, MSH was added to the model control wells, and MSH and the test sample were added to the experimental wells. The final concentration of the platinum particles tested for the sample was 0.5 ppm, and that of glabridin was 0.5 ppm. When the sample contains only platinum particles or glabridin, the concentration of the corresponding component is 0.5 ppm.

[0075] In each of the above groups, the culture plates added with the sample were placed in a CO2 incubator and cultured for about 65 h. After culture, the old medium was discarded, washed with PBS, digested with trypsin, the medium was added to stop digestion, a part of the suspension was taken for total protein quantification, and the rest was taken for melanin content detection. After washing with PBS, centrifuged to retain the precipitate, and left until the precipitate was dry.

[0076] Quantification of protein: The total protein of the cells was quantified using a kit.

[0077] Measurement of melanin content: According to the protein quantification result, a certain amount of 1 M NaOH was added to the centrifuge tube so that the concentration of the total protein in the solution in each tube was the same.

[0078] The NaOH cell suspension was heated at 80°C for 10 min to dissolve and disperse all cell clumps into a uniform solution, the OD value was measured at 405 nm, three samples were repeated for each group of components, and the calculation results were averaged. Calculation formula for melanin inhibition rate = (model group - sample group) / (model group - blank group) × 100%. The test results are shown in Table 5.

[0079] Test results of cell melanin inhibition rate JPEG0007712457000006.jpg22170

[0080] Comparative sample 4 is a free gramine solution. When the cell test concentration is 0.5 ppm, the melanin synthesis inhibition rate in B16 cells is 41.9%. By binding gramine to platinum particles (semi-finished product 1) or encapsulating it with liposomes (comparative sample 1), the melanin inhibition effect at the same concentration can be improved to 57.1% and 54.5% respectively. By encapsulating platinum particles and gramine simultaneously with liposomes (comparative sample 2), the melanin inhibition effect at the same concentration is further improved, and the inhibition rate reaches 68.3%. By modifying platinum particles to carry gramine molecules and then encapsulating them with liposomes, the melanin inhibition rate of B16 cells at the same concentration is significantly improved, which is better than that of control sample 2. This shows that the present invention can significantly improve the whitening effect of the active substance.

[0081] 2. Test on gene expression level of cell inflammatory factors Collect the THP-1 cell suspension stably passaged in a culture flask, transfer it to a 15 mL centrifuge tube, centrifuge at 1000 rpm / min for 5 minutes, discard the supernatant, resuspend the cells in 8 mL of complete medium, and count them using a cell counter. A cell suspension containing 5×10 5 individual THP-1 cells was sequentially inoculated into each well of a 24-well plate, and complete medium was added until the total volume in the well reached 0.5 mL.

[0082] A blank control group, a model group, and a sample group were set up. 0.5 mL of complete medium was added to the blank control group and the corresponding wells, and 0.5 mL of the sample working solution at a concentration twice the final concentration determined by the test was added to the wells corresponding to the sample group. They were shaken uniformly and cultured in an incubator for 18 - 24 h. As a result of testing the sample, the final concentration of platinum was 0.8 ppm, and the final concentration of madekassoside was 2 ppm. When the sample contains only platinum particles or madekassoside, the final concentration of the platinum particles tested for the sample is 0.8 ppm, or the madekassoside is 2 ppm.

[0083] To make the final concentration of LPS in the well approximately 1 μg / mL, 10 μL of the LPS working solution (100 μg / mL) was added to each corresponding well of the model group and the sample group for stimulation. They were shaken uniformly and cultured in an incubator for 24 h. The cells in the wells of each group were collected, and total RNA was extracted from the cells of each group using an RNA extraction kit. Using a transcription kit, the total RNA of the cells in each group was reverse transcribed into cDNA. Using GAPDH as an internal standard, the relative expression levels of TNF-α and IL-1β in each group were detected.

[0084] Calculation formula for the inhibition rate of inflammatory factors = (model group - sample group) / (model group - blank group) × 100%

[0085] The test results are shown in Table 6.

[0086] Test Results of Cell Inflammatory Factors JPEG0007712457000007.jpg27170

[0087] Comparative sample 8 is a free madecaside solution. When the cell test concentration was 2 ppm, the TNF-α and IL-1β inhibition rates of THP1 were 33.1% and 11.8% respectively. By binding madecaside to platinum particles (semi-finished product 5) or encapsulating it with liposomes (comparative sample 5), the inhibitory effects on inflammation expression at the same concentration can be improved to 41%, 15.6%, 42.9%, and 15.3% respectively. By simply mixing platinum particles and madecaside and encapsulating them with liposomes (comparative sample 6), the inhibitory effect on inflammation expression at the same concentration was further improved, and the inhibition rates were 46.2% and 17.1%. By modifying platinum particles to carry madecaside molecules and then encapsulating them with liposomes, the inhibition rate of inflammatory factor expression in THP1 cells at the same concentration was significantly improved, which was better than that of control sample 6. This shows that the present invention can significantly improve the anti-inflammatory effect of the active substance.

[0088] 3. Test of clinical moisturizing effect In the experiment, 10 female subjects aged 35 to 45 were selected, and four test areas (3 cm × 3 cm) on the inner sides of the left and right arms were marked as eight groups of test areas. The test sample was a 1% aqueous dilution solution of Example 10 - Sample 9. The platinum content and sodium hyaluronate content of the remaining samples were consistent with the content of the samples. The dilution solvent was all pure water, and the blank group was pure water.

[0089] In a thermostatic and humid chamber, after the subjects sat quietly for 30 minutes, the experimenter used a Corneometer CM825 device to measure the water content of the skin in each area in turn (T0 before using the sample). Then, 18 mg of the sample corresponding to each area of the subject was applied in the order of the test areas and evenly spread. After that, the Corneometer CM825 device was used to measure the water content value of the skin in each area at the corresponding test node in turn. In this test, a total of four test nodes were selected (T0 before using the sample, T 30 30 minutes after using the sample, T 60 60 minutes after using the sample, and T 90) After the test, the data was statistically analyzed to calculate the average water content of the samples in each group and the increase rate of skin water content.

[0090] Calculation formula for the increase rate of skin water content = (T 時間 - T0) / T0 × 100%

[0091] The test results are shown in Table 7.

[0092] Test results of the human body moisturizing effect JPEG0007712457000008.jpg48170

[0093] Comparative sample 12 is sodium hyaluronate, which has the effect of significantly increasing the water content within 90 minutes after being applied to the skin, and is equivalent to the moisturizing effect when combined with platinum particles in Example 3. When sodium hyaluronate is bound to platinum particles (Example 6 - semi - product 9), its moisturizing effect on the skin is significantly better than that of the simple mixing group, indicating that the combination of platinum particles and sodium hyaluronate can affect the water content state of the skin and enhance the moisturizing effect. In Comparative Example 8 - Comparative sample 10 and Comparative Example 7 - Comparative sample 9, encapsulating sodium hyaluronate with liposomes can further improve the overall moisturizing effect. In Example 10 - sample 9, platinum particles modified with liposome - encapsulated sodium hyaluronate have a better moisturizing effect than liposomes without modified platinum, indicating that liposomes can synergistically enhance the action of sodium hyaluronate - modified platinum particles and exert the optimal moisturizing effect.

[0094] 4. Test on the expression level of the collagen - synthesizing gene in cells Well - growing NHDF cells in the logarithmic growth phase were counted and inoculated into 6 - well plates at 2.0×10 5 cells / well, cultured overnight in an incubator, and the old medium was discarded.

[0095] Sample group: 2 mL of the test solution of the example or the test solution of the comparative example (manufactured using a complete medium) was added. As a result of testing the sample, the final concentrations of platinum and palmitoyl tripeptide-5 were 1 ppm and 1 ppm, respectively. When the sample contains only platinum particles or palmitoyl tripeptide-5, the final concentrations of both platinum particles or madekasoside tested for the sample are 1 ppm.

[0096] Blank group and model group: 2 mL of a complete medium was added.

[0097] In each of the above groups, after adding the sample, the cells were cultured for 24 h. After culturing, the old medium was discarded, the cells were washed with PBS, and 2 mL of HBSS was added. The cells in the model group and the sample group were placed in an ultraviolet spectrophotometer and irradiated with a UVA dose of 30 J / cm 2 The blank control group blocked ultraviolet light using aluminum foil. After irradiation, the HBSS in the well was discarded, the cells were washed with PBS, 2 mL of the test solution of the example or the test solution of the comparative example (manufactured using a complete medium) was added to the sample group, 2 mL of a complete medium was added to the blank group and the model group, and the culture was continued for 24 h in an incubator.

[0098] Total RNA was extracted from the cells of each group using an RNA extraction kit, and the total RNA from the cells of each group was reverse transcribed into cDNA using a reverse transcription kit. Using GAPDH as an internal reference, the relative expression levels of COL1A1 in each group were detected.

[0099] Calculation formula for the rate of improvement in collagen synthesis = (sample group - model group) / (model group) × 100%

[0100] The test results are shown in Table 8.

[0101] Test results of the expression levels of cell collagen synthesis genes JPEG0007712457000009.jpg27170

[0102] Comparative sample 16 is a free palmitoyl tripeptide-5 solution. When the cell test concentration was 1 ppm, the expression rate of the type I collagen synthesis gene in NHDF cells was improved by 27%. By binding palmitoyl tripeptide-5 to platinum particles (semi-finished product 10) or encapsulating it with liposomes (comparative sample 14), the collagen synthesis effect at the same concentration can be improved by 34.7% and 35.3% respectively. By simply mixing platinum particles and madekasoside and encapsulating them with liposomes (comparative sample 15), the collagen synthesis effect at the same concentration can be further improved, with an improvement rate of 53%, which is comparable to the sum of the improvement effects of platinum particles and liposomes, but there is no synergistic effect. After modifying platinum particles to carry palmitoyl tripeptide-5 molecules and then encapsulating them with liposomes, the collagen synthesis rate of NHDF cells at the same concentration was significantly improved, which was better than that of control sample 15. This shows that the present invention can significantly improve the anti-aging effect of the active substance.

Claims

**Claim 1** A composition comprising a carrier, said carrier comprising liposomes and platinum encapsulated in the liposomes, wherein a cosmetic active ingredient is supported on the surface of the platinum, the weight ratio of the liposomes to the platinum is 100 to 500:1, the cosmetic active ingredient is madecassoside or palmitoyl tripeptide-5, the weight ratio of the platinum to the cosmetic active ingredient is 1:0.1 to 20, the particle diameter of the platinum is 3 to 200 nm, and the platinum connects the cosmetic active ingredient by physical action or chemical bonding. **Claim 2** Use of the composition according to claim 1 in the manufacture of cosmetics.

Images